Wave Life Sciences is trading at $3.49, up +10.09%, with biotech strength the clearest context; evidence points to a sector-led move, not a confirmed company-specific trigger.
- The biotech sector ETF is up about 2.1% during the regular session; sentiment was also supported by Merck KGaA’s agreement to acquire RNA-focused Silence Therapeutics for about $1.3 billion.
- Wave announced its third-quarter results call for October 27; its notice identified no new company-specific catalyst. Available sources established no trading-volume details.